retatrutide clinical trial information New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats A New Obesity Drug Delivered

Building on striking phase 2 data which showed mean body weight reductions of approximately 24% at the highest dose over 48 weeks retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, potentially offering a more powerful metabolic effect than existing treatments

The authors have declared that no competing interest exists

Results here will determine whether retatrutide can pursue a combined obesity-and-diabetes indication on its label, which matters commercially: diabetes coverage by Medicare and most commercial insurers is substantially broader than obesity-only coverage

Johns County, and all of Northeast Florida

Subsequently, the supernatant was collected and centrifuged repeated at 10.000 g at 4 C for 10 min to improve purification from cell detritus and platelets

Certificates of Analysis (CoA) are available upon request